Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > China deal

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Dec 27, 2021 2:10pm

101 Views

Post# 34264075

RE:RE:China deal

Often we speculate when a deal should be done earlier with less upfront payment, loyalties etc or later on when there has been some results, This company although they are further in process with their trial than THTX decided based on most likely some encouraging results so far to close a deal relatively early only based on interim results from their phase1 trial. In case of THTX if and when their results are also encouraging it does make sense to chase a similar deal overseas and China would be good place imo because they won't have the resources to sell their potential approved drug in North America let alone China also they do need funds. Let's hope on the back of good results they strike a good deal.

qwerty22 wrote:
Such a nice deal for them to secure.

scarlet1967 wrote:

“Tasly obtains exclusive development and commercialization rights for STRO-002 for Greater China -

- License includes a $40 million upfront payment to Sutro, and potentially up to $345 million in development and commercial milestone payments”

https://www.prnewswire.com/news-releases/sutro-biopharma-and-tasly-biopharmaceuticals-enter-into-exclusive-license-agreement-for-stro-002-in-greater-china-301450798.html

They will also discuss the interim data from their Phase 1 trial in January for their ADC.

https://finance.yahoo.com/news/sutro-biopharma-announces-company-kol-120000956.html